Swiss National Bank lifted its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 28.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 133,500 shares of the biopharmaceutical company’s stock after buying an additional 29,200 shares during the quarter. Swiss National Bank owned about 116,930.89% of Juno Therapeutics worth $5,989,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its position in shares of Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the period. Pacad Investment Ltd. acquired a new stake in shares of Juno Therapeutics during the second quarter worth $105,000. QS Investors LLC acquired a new stake in shares of Juno Therapeutics during the second quarter worth $135,000. Macquarie Group Ltd. acquired a new stake in shares of Juno Therapeutics during the second quarter worth $248,000. Finally, Leisure Capital Management acquired a new stake in shares of Juno Therapeutics during the second quarter worth $255,000. Institutional investors own 66.96% of the company’s stock.
Several research analysts recently issued reports on JUNO shares. Vetr raised shares of Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 target price on the stock in a research note on Monday, July 31st. Zacks Investment Research lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Morgan Stanley increased their target price on shares of Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Monday, August 7th. BTIG Research raised shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a research note on Monday, August 28th. Finally, Wedbush raised shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 target price on the stock in a research note on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. Juno Therapeutics has a consensus rating of “Hold” and an average target price of $44.20.
Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) opened at $58.77 on Wednesday. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $61.59.
Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. The company had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.57) earnings per share. sell-side analysts forecast that Juno Therapeutics, Inc. will post -4.02 EPS for the current fiscal year.
In related news, General Counsel Bernard J. Cassidy sold 28,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the completion of the sale, the general counsel now owns 55,970 shares in the company, valued at $2,514,172.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total transaction of $366,296.70. Following the sale, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The disclosure for this sale can be found here. Insiders have sold 79,670 shares of company stock valued at $3,553,777 in the last 90 days. 15.26% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Stake Raised by Swiss National Bank” was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/11/22/juno-therapeutics-inc-juno-stake-raised-by-swiss-national-bank.html.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.